• Repurposing Drugs for CMT1A: An Encouraging Approach
    Charcot-Marie-Tooth disease type 1A (CMT1A) is the most common form of CMT, caused by having an extra copy of the PMP22 gene. This results in PMP22 overexpression, leading to excessive PMP22 protein in Schwann cells, ...
    Read more ...
  • DNA-Based Therapeutics: A Promising Future for CMT2E Treatment
    Researchers at the University of Miami, supported by the Charcot-Marie-Tooth Association (CMTA) and its Strategy To Accelerate Research (STAR) and led by CMTA-STAR Advisory Board member Mario Saporta, MD, PhD, have made significant progress in ...
    Read more ...
  • CMT-SORD: Share Your Story
    CMT-SORD: What is Your Story? For many with CMT, the journey through diagnosis, acceptance, and living with this progressive disease can be isolating. Most research is conducted through a clinical lens that aims to improve symptoms. ...
    Read more ...
  • Chris Oviatt – Golfer with CMT
    Chris Oviatt is a golfer from Oregon who was diagnosed with Charcot-Marie-Tooth disease (CMT) in 1987. As she prepares for the US Adaptive Open in Kansas, Chris took time to chat with CMTA’s CEO Dr. ...
    Read more ...
  • CMTA Announces New Center of Excellence in Thailand
    The Charcot-Marie-Tooth Association (CMTA), the world’s largest philanthropic funder of research aimed at bringing treatments to patients and improving the lives of those living with Charcot-Marie-Tooth disease (CMT), is excited to announce it has awarded ...
    Read more ...